MHA's road maps provide hospitals and health systems with evidence-based recommendations and standards for the development of topic-specific prevention and quality improvement programs, and are intended to align process improvements with outcome data. Road maps reflect published literature and guidance from relevant professional organizations and regulatory agencies, as well as identified proven practices. MHA quality and patient safety committees provide expert guidance and oversight to the various road maps.

Each road map is tiered into fundamental and advanced strategies:
- **Fundamental strategies** should be prioritized for implementation, and generally have a strong evidence base in published literature in addition to being supported by multiple professional bodies and regulatory agencies.
- **Advanced strategies** should be considered in addition to fundamental strategies when there is evidence the fundamental strategies are being implemented and adhered to consistently and there is evidence that rates are not decreasing and/or the pathogenesis (morbidity/mortality among patients) has changed.

**Operational definitions** are included to assist facility teams with road map auditing and identifying whether current work meets the intention behind each road map element.

**Resources** linked within the road map include journal articles, expert recommendations, electronic order sets and other pertinent tools which organizations need to assist in implementation of best practices.

**It is important to note that appropriate testing for CDI is critical for best practice implementation and patient outcomes. The best practices are appropriate for patients with signs and symptoms compatible with CDI (e.g., clinically significant diarrhea). Some patients may have the bacteria without signs or symptoms of infection – testing asymptomatic patients is not clinically useful, and may lead to unnecessary antibiotic use.**

**Additionally, the road map includes planning for CDI outbreak situations whereby some of the advanced measures for patient isolation and cleaning/disinfection become fundamental.**

<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
</table>
| **CDI surveillance** | **FUNDAMENTAL**  
*(check each box if “yes”)*  
☐ The facility’s CDI surveillance processes include monitoring CDI diagnoses and management within the facility [1,2].  
☐ CDI audit and surveillance data is provided to environmental services leadership and staff [1,3]. | Surveillance is the foundation of infection prevention efforts. The National Healthcare Safety Network (NHSN) provides standardized definitions for reporting through their [Multidrug-Resistant Organism & Clostridioides difficile Infection (MDRO/CDI) Module](#).  
The Greater New York Hospital Association United Hospital Fund, Appendix C has a useful [CDI Tracking Tool](#). |
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
</table>
| CDI surveillance, continued | **ADVANCED** *(check each box if “yes”)*  
- Surveillance for colectomies associated with CDI [3] is included in the facility’s CDI surveillance processes.  
- Root cause analyses are conducted for colectomies/deaths associated with CDI [3]. |  |
| Early detection and appropriate testing | **FUNDAMENTAL** *(check each box if “yes”)*  
- Timely communication is provided to the health care provider that a patient is suspected of having CDI [1].  
- Appropriate health care personnel (HCP) are trained to obtain only unformed stool samples for laboratory testing of patients suspected of having CDI.  
- Healthcare personnel are trained to recognize the signs/symptoms of CDI. | [Clostridiodes (Clostridium) difficile Guidelines and Resources](#) |
| Laboratory processes for CDI testing | **FUNDAMENTAL** *(check each box if “yes”)*  
- The facility has a lab testing method that enhances the sensitivity and specificity of CDI detection [1].  
  - If the facility has diagnostic testing criteria [See “Clinical processes for CDI testing”] in place, consider using only a nucleic acid amplification test [NAAT].  
  - If the facility does not have diagnostic testing criteria [See “Clinical processes for CDI testing”], consider using a stool toxin test as part of a multistep algorithm rather than a NAAT alone.  
- A process is in place to limit CDI testing for pediatric patients.  
  - The process includes a notification process for testing pediatric patients. For example, the electronic health record includes a prompt/flag to electronically alert staff regarding patients who do not meet the age criteria for testing, per facility policy. | The Minnesota Department of Health has developed a summary reviewing different laboratory tests for Clostridiodes Difficile infection.  
Limiting CDI testing to patients with a reasonable probability of having the disease helps avoid detection of colonized patients. Consider the following when developing processes which support appropriate testing practices:  
- HRET (2017), Clostridium difficile Infection Change Package (Appendix III: Vanderbilt EHR screenshots)  
- Choosing Wisely (2019), SHEA urinalysis, urine culture, blood culture or C. difficile testing  
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
</table>
| Laboratory processes for CDI testing, continued | **ADVANCED**  
*(check each box if “yes”)*  
☐ When testing for CDI, the facility uses a multistep algorithm for testing referenced in the 2018 SHEA guidelines or in the ACG clinical guidelines. [1,2,3] | • MHA developed a [calculation tool](#) for estimating the expected number of hospital-onset CDI based on the NHSN CDI SIR model. |
| | **FUNDAMENTAL**  
*(check each box if “yes”)*  
☐ The facility has a process in place to limit diagnostic testing for CDI to only symptomatic patients [1,2].  
☐ Do not test formed stool.  
☐ Diarrheal symptoms such as patients with unexplained and new-onset ≥ 3 unformed stools in 24 hours [1,2].  
☐ Avoiding testing when diarrheal symptoms may be attributable to therapies such as tube feeding, intensive cancer chemotherapy or laxatives; or underlying conditions such as inflammatory bowel disease [1].  
☐ Clinical symptoms such as fever, elevated white blood cell count or abdominal pain.  
- CDI diagnostic process includes submitting one stool specimen for initial CDI testing [2], and not conducting repeat testing (within 7 days) during the same episode of diarrhea for confirmed CDI patients [1,2,5].  
☐ Do not retest within 7 days.  
☐ “Tests of cure” are not conducted post treatment [1,2,5].  
☐ The facility has a process in place for diagnostic testing of pediatric patients. The process includes [1,6]:  
- Patients ≤ 24 months of age: not routinely testing for CDI unless other infectious or noninfectious causes have been excluded.  
- Children ≥2 years of age: testing for CDI in patients with prolonged or worsening diarrhea and risk factors (e.g., underlying inflammatory bowel disease, history of GI surgery, immunocompromising conditions) or relevant exposures (e.g., prolonged, frequent or recent hospitalization or frequent or recent antibiotics).  
- Non-diarrheal indications of CDI include marked leukocytosis, toxic megacolon, ileus, pseudomembranous colitis | Limiting CDI testing to patients with a reasonable probability of having disease helps avoid detection of colonized patients. Consider the following when developing processes which support appropriate testing practices:  
• [HRET (2017), Clostridium difficile Infection Change Package (Appendix IX: UW Health Adult Inpatient Testing Algorithm for Clostridium difficile Infection)](#)  
• [Vanderbilt University Medical Center (2019), Guidance to Providers: Testing for C. difficile Infection](#)  
• University of California San Francisco [Diarrhea Decision Tree](#)  
• Intermountain Healthcare [Best Practice Flash Card for C. difficile](#)  
• [University of Michigan Medicine Clinical Guideline for Clostridiodes Difficile Infection in Adults and Children](#)  
• [Sinai Health System University Health Network Antimicrobial Stewardship Program First Episode Clostridium difficile Infection (CDI) Management Algorithm](#)  
• [Testing Algorithm for Clostridiodes Difficile Infection (CDI), clinical guidelines for ages>24 months, Children’s MN](#)  
• [Clostridiodes Difficile Infection (CDI) Treatment Guideline, ages<18 years old, Children’s MN](#)  
• [New and revised requirements addressing antibiotic stewardship for the hospital and critical access hospital programs, The Joint Commission, effective January 1, 2023](#)  
• [Minnesota One Health Antibiotic Stewardship Collaborative](#) |
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</td>
<td>If specific road map element is missing, consider the following resources:</td>
<td></td>
</tr>
<tr>
<td>Clinical processes for CDI testing, continued</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ The facility has a process in place for timely communication of CDI test results [1,3,4,7].</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Includes timely communication to: patient care unit/facility, provider, infection prevention, and patient and/or family.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient engagement is an important component of CDI prevention and treatment. Consider the following examples when developing teaching materials:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CDC C. diff patient education materials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Mount Sinai Hospital Special Isolation Precautions for Clostridioides difficile (C. difficile)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The Ohio State University Medical Center Clostridioides Difficile (C. diff) Colitis: Care Instructions difficile patient education</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Isolation precautions help prevent infections that are spread through touch in the environment. Consider the following when developing organizational processes for the use of precautions:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CDC FAQs for Clinicians about C. diff</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CDC Clostridioides difficile Infection (CDI) Toolkit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CDC (2021) Strategies to Prevent Clostridioides difficile Infection in Acute Care Facilities</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• MHA Controlling CDI Environmental Cleaning Training and Supervision Tool Kit, Precautions signs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• University of California San Francisco Diarrhea Decision Tree</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HRET. Clostridium difficile Infection Change Package (Appendix VIII Diarrhea/Enhanced Precautions Decision Tree); 2017 Update</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HRET (2017) Clostridium difficile Infection Change Package (Appendix VII; Diarrhea Decision Tree)</td>
</tr>
<tr>
<td>Patient &amp; family education</td>
<td>☐ The facility has a process in place to educate patients diagnosed with CDI.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Patient education includes topics such as symptoms of CDI, what the health care personnel/prescribers are doing to prevent infection and what the patient can do to help prevent an infection. [1]</td>
<td></td>
</tr>
<tr>
<td>Isolation precautions</td>
<td>☐ Patients with confirmed CDI are placed in a private room [1-4,7-9] with a bathroom or bedside commode solely for use by patient [3].</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ HCP and prescribers perform hand hygiene and don gloves and gown prior to entering patient room [1-4,7-10].</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Hand hygiene is performed before and after entering the CDI patient room (to coincide with before patient contact and after removing gloves) with soap and water or an alcohol-based product [1-4,7-10].</td>
<td></td>
</tr>
<tr>
<td></td>
<td>☐ Isolation precautions are continued for at least 48 hours after diarrhea has resolved [1].</td>
<td></td>
</tr>
</tbody>
</table>
## Isolation Precautions, Continued

**ADVANCED**

*(check each box if “yes”)*

- Use of soap and water, for hand hygiene, is the preferred method.
- The facility preferentially places incontinent patients suspected of having CDI in private rooms having priority when private room availability is limited [1,3].
- The facility preemptively places patients with loose stools (e.g., ≥3 unformed stools in 24 hours) in isolation precautions [1,3,7].
- When using preemptive isolation precautions, patients are removed from isolation precautions if CDI test is negative and other infectious agents that require isolation precautions have been ruled out.
- Isolation precautions are continued for the duration of the current hospitalization for confirmed CDI patients, even if diarrhea resolves [1,3,7,8].
- Universal glove use is implemented on floors/units/areas with endemic rates or ongoing transmission of CDI [4,7].
- Increasing frequency and/or scope of monitoring compliance with isolation precautions and hand hygiene [1,3,7].

## Strategies to Implement in Settings with an Outbreak or Increased CDI Rate

**FUNDAMENTAL**

*(check each box if “yes”)*

- The facility has a process in place for implementing isolation precautions in settings in which there is an outbreak or an increased CDI rate.
  - Preferentially placing incontinent patients in private rooms if private room availability is limited [1,3].
  - Patients are removed from preemptive isolation precautions if CDI test is negative and other infectious agents that require isolation precautions have been ruled out.
  - Increasing frequency and/or scope of monitoring compliance with isolation precautions and hand hygiene [1,3,7].

The CDC developed a [Targeted Assessment for Prevention (TAP) framework](https://www.cdc.gov/hai/tap/) for quality improvement which helps organizations use data for action in the prevention of infections. The TAP strategy supports facilities in identifying locations within facilities with a disproportionate burden of infections so that prevention resources can be used most effectively.
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
</table>
| Strategies to implement in settings with an outbreak or increased CDI rate, continued | ☐ The facility has a process in place for performing hand hygiene in settings in which there is an outbreak or an increased CDI rate.  
☐ Perform hand hygiene with soap and water preferentially instead of alcohol-based hand hygiene products after caring for a CDI patient [1-4,7,9,10].  
☐ Implementing universal glove use on floors/units/areas [4,7].  
☐ The facility's cleaning and disinfection processes include conducting an evaluation of the use of chlorine-containing or other sporicidal product/technology used for daily and terminal environmental disinfection for all patient rooms and patient care equipment on affected unit if transmission is ongoing [2,3,7,9,11]. | Environmental cleaning is a critical component of CDI prevention. Consider the following resources when developing cleaning and disinfection processes:  
- MHA Environmental Services Cleaning Guidebook  
- MHA CDI Environmental Cleaning in the O.R. and the E.D. toolkit  
- MHA webinar: Environmental Interventions to Reduce *Clostridioides difficile*  
- CDC Options for Evaluating Environmental Cleaning  
- CDC Environmental Checklist for Monitoring Terminal Cleaning  
- CDC Environmental Cleaning Evaluation Worksheet  
- CDC Options for Evaluating Environmental Cleaning [See: Level II]  
- MHA UV Gel Testing Procedure |

**FUNDAMENTAL**  
*(check each box if “yes”)*  
☐ The environmental services director and infection preventionist partner to ensure effective cleaning and disinfection strategies [3].  
☐ Environmental services staff is notified of patient rooms requiring enhanced cleaning and disinfection.  
☐ Chlorine-containing or other sporicidal product/technology is used for daily and terminal environmental disinfection for all CDI patient rooms and patient care equipment, per organizational policy [1,3,4].  
☐ The routine cleaning and disinfection processes are evaluated periodically through direct practice observation to ensure compliance with best practices.  
- For example, use a visual inspection process with checklist. |  |

**ADVANCED**  
*(check each box if “yes”)*  
☐ The facility’s cleaning and disinfection processes include an evaluation of the use of chlorine-containing or other sporicidal product/technology used for daily and terminal environmental disinfection for all patient rooms and patient care equipment on CDI-affected unit if transmission is ongoing [2,3,7-9,11].  
☐ Routine cleaning/disinfection processes are evaluated periodically through a technology-based approach using a biochemical product (e.g., fluorescent markers, ATP bioluminescence, cultures) [1,3,4,7]. |  |
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimicrobial stewardship &amp; medication management</strong></td>
<td></td>
<td>Antimicrobial stewardship is an essential component of reducing the incidence of CDI infection. Facility antibiotic stewardship programs should follow the CDC <a href="https://www.cdc.gov/antibiotic-use/antibiotic-stewardship/core-elements.html">Core Elements of Hospital Antibiotic Stewardship Programs</a>. Consider the following selected implementation resources to support antibiotic stewardship work:</td>
</tr>
</tbody>
</table>
| **FUNDAMENTAL** (check each box if “yes”) | - The facility has an antibiotic stewardship program that follows the Centers for Disease Control and Prevention’s Core Elements of Hospital Antibiotic Stewardship Programs [12,13].<br>- The facility collaborates with medical staff to set clear expectations for appropriate antibiotic use and follows current national recommendations for CDI diagnosis and management, e.g., guidelines developed by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [2] and the American College of Gastroenterology [5].<br>- Appropriate CDI patient management includes: avoiding antiperistaltic agents for patients suspected/diagnosed with CDI [2,5]; Consultation with specialists when persistent, recurrent or worsening CDI is identified (e.g., infectious disease physician, gastroenterologists, general surgeons). | - CDC [Implementation of Antibiotic Stewardship Core Elements at Small and Critical Access Hospitals](https://www.cdc.gov/antibiotic-use/antibiotic-stewardship/core-elements.html)  
- MHA Antibiotic Stewardship collaborative [webinars](https://www.mnhospital.org/antibiotic-stewardship) |
<p>| <strong>Performance improvement monitoring</strong> |                                                                                                                | Surveillance is the foundation of infection prevention efforts. The National Healthcare Safety Network (NHSN) provides standardized definitions for reporting through their <a href="https://www.cdc.gov/nhsn/PDFs/program-specific/MDRO/CDI-module.pdf">Multidrug-Resistant Organism &amp; Clostridioides difficile Infection (MDRO/CDI) Module</a>. The Greater New York Hospital Association United Hospital Fund, Appendix C has a useful <a href="https://www.gnyhospital.org/antimicrobial-stewardship">CDI Tracking Tool</a>. |</p>
<table>
<thead>
<tr>
<th>Road map sections</th>
<th>Road map questions (if not present at your hospital or answering no, please see next column for suggested resources)</th>
<th>If specific road map element is missing, consider the following resources:</th>
</tr>
</thead>
</table>
| Staff education   | **FUNDAMENTAL**  
(check each box if “yes”) | Education in basic CDI prevention, including hand hygiene, should be provided to multidisciplinary staff with potential for exposure to patients and/or infectious materials. Consider the following resources when developing staff education materials:  
- MHA “Cleaning Protocol for Environmental Services” Lecture 2014-2016  
- CDC Clean Hands Count, Education Module: “Hand Hygiene, Glove Use, and Preventing Transmission of C. difficile (2017)”  
- Greater New York Hospital Association United Hospital Fund, Reducing C. Difficile Infections Toolkit (Appendix G: Environmental Services Training Video and Presentation) 2011 |

**REFERENCES**


